Chi Jeffrey 4
4 · Aardvark Therapeutics, Inc. · Filed Feb 19, 2025
Insider Transaction Report
Form 4
Chi Jeffrey
Director
Transactions
- Conversion
Common Stock
2025-02-14+133,364→ 133,364 total(indirect: By LLC) - Conversion
Series C Convertible Preferred Stock
2025-02-14−1,130,135→ 0 total(indirect: By LLC)→ Common Stock (133,364 underlying)
Footnotes (2)
- [F1]The Series C Convertible Preferred Stock of Aardvark Therapeutics, Inc. (the "Issuer") automatically converted on an 8.474-for-1 basis into shares of the Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The Series C Convertible Preferred Stock had no expiration date.
- [F2]Vickers Venture Co-investment LLC ("Vickers Co-investment") is managed by Vickers Venture Partners (S) Pte. Ltd. which is in turn managed by its directors, being Dr. Jeffrey Chi and Dr. Finian Tan, who collectively exercise sole voting and dispositive power over the securities held by Vickers Co-investment. Each of Vickers Venture Partners (S) Pte. Ltd., Dr. Jeffrey Chi and Dr. Finian Tan disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein.